Why would a pharma company consult an advisory board when starting development of a new drug?

Why would a pharma company consult an advisory board when starting development of a new drug?

• A. To expedite manufacturing
• B. To provide their opinion on the research and development of the drug
• C. To handle marketing responsibilities
• D. To set pricing

Answer: (B)

At the start of developing a new drug, a pharma company benefits from external, independent scientific input to shape the plan. An advisory board brings clinicians, researchers, and other experts who review the proposed research and development strategy, including trial design, endpoints, patient populations, and regulatory considerations. Their input helps ensure the studies are scientifically sound, feasible, and aligned with current knowledge and regulatory expectations, reducing risks and guiding resource use. They advise on how to approach the development path, interpret data, and foresee potential challenges, which is essential for building a credible, robust program. Expediting manufacturing, handling marketing responsibilities, or setting pricing are separate functions handled by internal teams or different partners and typically occur later in the lifecycle or outside the core advisory role.

At the start of developing a new drug, a pharma company benefits from external, independent scientific input to shape the plan. An advisory board brings clinicians, researchers, and other experts who review the proposed research and development strategy, including trial design, endpoints, patient populations, and regulatory considerations. Their input helps ensure the studies are scientifically sound, feasible, and aligned with current knowledge and regulatory expectations, reducing risks and guiding resource use. They advise on how to approach the development path, interpret data, and foresee potential challenges, which is essential for building a credible, robust program.

Expediting manufacturing, handling marketing responsibilities, or setting pricing are separate functions handled by internal teams or different partners and typically occur later in the lifecycle or outside the core advisory role.